Summit Therapeutics (SMMT) Assets Average (2016 - 2025)
Historic Assets Average for Summit Therapeutics (SMMT) over the last 10 years, with Q3 2025 value amounting to $292.9 million.
- Summit Therapeutics' Assets Average fell 3065.46% to $292.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $292.9 million, marking a year-over-year decrease of 3065.46%. This contributed to the annual value of $319.3 million for FY2024, which is 2636.41% down from last year.
- Latest data reveals that Summit Therapeutics reported Assets Average of $292.9 million as of Q3 2025, which was down 3065.46% from $353.9 million recorded in Q2 2025.
- Over the past 5 years, Summit Therapeutics' Assets Average peaked at $469.2 million during Q4 2024, and registered a low of $106.1 million during Q2 2022.
- Its 5-year average for Assets Average is $253.7 million, with a median of $227.9 million in 2023.
- In the last 5 years, Summit Therapeutics' Assets Average surged by 29986.12% in 2023 and then tumbled by 5868.3% in 2024.
- Over the past 5 years, Summit Therapeutics' Assets Average (Quarter) stood at $121.0 million in 2021, then surged by 238.57% to $409.7 million in 2022, then tumbled by 48.58% to $210.7 million in 2023, then soared by 122.68% to $469.2 million in 2024, then tumbled by 37.58% to $292.9 million in 2025.
- Its last three reported values are $292.9 million in Q3 2025, $353.9 million for Q2 2025, and $409.7 million during Q1 2025.